Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease
NCT07902206, Not applicable, Not yet recruiting, Universidad de Burgos
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease | ClinicalTrials.gov |
| NCT number | NCT07902206 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 88 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universidad de Burgos | ClinicalTrials.gov |
| Conditions | Huntington Disease, Sarcopenia, Frailty | ClinicalTrials.gov |
| Interventions | Creatine monohydrate, Beta-hydroxy-beta-methylbutyrate (HMB), Placebo (microcrystalline cellulose), Home-based multicomponent exercise program | ClinicalTrials.gov |
| First posted | 2026-10-28 | ClinicalTrials.gov |
| Last updated | 2026-10-28 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Total Functional Capacity (TFC) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Unified Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity score, range 0-13; higher scores indicate better functional capacity. Change from baseline will be compared across the four arms. | ClinicalTrials.gov |
| Secondary | Change in Functional Assessment Scale (FAS) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | UHDRS Functional Assessment Scale, 25 yes/no items, range 0-25; higher scores indicate better function. | ClinicalTrials.gov |
| Secondary | Change in Independence Scale (IS) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | UHDRS Independence Scale, range 10-100 in 5-point steps; higher scores indicate greater independence. | ClinicalTrials.gov |
| Secondary | Change in Gait Speed | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Usual gait speed (m/s) measured over a standardized walking course. | ClinicalTrials.gov |
| Secondary | Change in Rate of Force Development (RFD) 0-200 ms | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Rate of force development (RFD) from 0 to 200 ms (N/s) during maximal isometric knee extension measured with a force transducer (best of three 5-s trials). | ClinicalTrials.gov |
| Secondary | Change in Peak Force | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Peak force (N) during maximal isometric knee extension measured with a force transducer (best of three 5-s trials). | ClinicalTrials.gov |
| Secondary | Change in Contraction Time | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Contraction time (ms) during maximal isometric knee extension measured with a force transducer (best of three 5-s trials). | ClinicalTrials.gov |
| Secondary | Change in Fat-Free Mass (FFM) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Fat-free mass (FFM, kg) assessed by multifrequency bioelectrical impedance analysis (BIA). | ClinicalTrials.gov |
| Secondary | Change in Fat Mass (FM) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Fat mass (FM, kg) assessed by multifrequency bioelectrical impedance analysis (BIA). | ClinicalTrials.gov |
| Secondary | Change in Fat-Free Mass Index (FFMI) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Fat-free mass index (FFMI, kg/m\^2) assessed by multifrequency bioelectrical impedance analysis (BIA). | ClinicalTrials.gov |
| Secondary | Change in Fat Mass Index (FMI) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Fat mass index (FMI, kg/m\^2) assessed by multifrequency bioelectrical impedance analysis (BIA). | ClinicalTrials.gov |
| Secondary | Change in Mini-Mental State Examination (MMSE) Score | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | MMSE total score, range 0-30; higher scores indicate better global cognitive function. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in Symbol Digit Modalities Test (SDMT), Oral Version | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Number of correct responses in 90 seconds on the oral version of the SDMT; higher scores indicate better performance. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in Stroop Test Performance | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Number of correct responses in 45 seconds on the Stroop test; higher scores indicate better performance. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in Trail Making Test Part A (TMT-A) Completion Time | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Time to complete Trail Making Test Part A (seconds); lower values indicate better performance. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in Trail Making Test Part B (TMT-B) Completion Time | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Time to complete Trail Making Test Part B (seconds); lower values indicate better performance. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in Semantic Verbal Fluency | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Number of words produced in 60 seconds in a semantic (category) verbal fluency task; higher scores indicate better performance. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in Phonemic Verbal Fluency | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | Number of words produced in 60 seconds in a phonemic (letter) verbal fluency task; higher scores indicate better performance. Part of the Enroll-HD cognitive battery. | ClinicalTrials.gov |
| Secondary | Change in 12-Item Short Form Health Survey (SF-12) Physical Component Summary (PCS) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | SF-12 Physical Component Summary score, range 0-100; higher scores indicate better physical health-related quality of life. | ClinicalTrials.gov |
| Secondary | Change in 12-Item Short Form Health Survey (SF-12) Mental Component Summary (MCS) | Baseline, week 12 (end of intervention) and 6 months after the end of intervention | SF-12 Mental Component Summary score, range 0-100; higher scores indicate better mental health-related quality of life. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)